These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1929295)

  • 1. In vitro activity of YM133, a new semisynthesized macrolide.
    Terasawa T; Watanabe M; Okubo T; Mitsuhashi S
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1370-5. PubMed ID: 1929295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial activity of rokitamycin compared with that of other macrolides.
    Yu KW; Briones F; Chin NX; Neu HC
    Diagn Microbiol Infect Dis; 1991; 14(4):331-5. PubMed ID: 1889182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the degree of susceptibility of Streptococcus pyogenes erythromycin-resistant strains to rokitamycin (a 16-membered macrolide) using the Epsilometer test.
    Crotti D; Rossetti R; Braga PC
    Drugs Exp Clin Res; 2004; 30(1):17-26. PubMed ID: 15134387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of MC-352, a new 16-membered macrolide.
    Chin NX; Neu HC
    Antimicrob Agents Chemother; 1992 Aug; 36(8):1699-702. PubMed ID: 1416853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro antibacterial activity of a new macrolide: miokamycin. Comparison with erythromycin and josamycin].
    Soussy CJ; Leclercq R; Duval J
    Pathol Biol (Paris); 1988 May; 36(5):370-6. PubMed ID: 3043331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
    Mazzariol A; Koncan R; Vitali LA; Cornaglia G
    J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998. Spanish Group for the Study of Infection in the Primary Health Care Setting.
    Alós JI; Aracil B; Oteo J; Torres C; Gómez-Garcés JL
    J Antimicrob Chemother; 2000 May; 45(5):605-9. PubMed ID: 10797081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The post-antibiotic effects of rokitamycin (a 16-membered ring macrolide) on susceptible and erythromycin-resistant strains of Streptococcus pyogenes.
    Braga PC; Culici M; Dal Sasso M
    Int J Antimicrob Agents; 2004 Sep; 24(3):254-60. PubMed ID: 15325429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antimicrobial activities of macrolides against recent clinical isolates, and analysis of resistant mechanisms].
    Okubo T; Iyobe S; Fujiki Y; Sagai H
    Jpn J Antibiot; 2003 Jun; 56(3):163-70. PubMed ID: 12942787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro antibacterial activity of rokitamycin, a new macrolide antibiotic. Results of a multicenter study].
    Soussy CJ; Le Van Thoi J; Meyran M; Joly B; Derlot E; Morel C
    Pathol Biol (Paris); 1990 May; 38(5):407-12. PubMed ID: 2195450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Josamycin: interpretation of inhibition zones with the Bauer-Kirby agar disk diffusion test as compared with erythromycin.
    Karthein J; Spohr M; Traub WH
    Chemotherapy; 1986; 32(4):336-43. PubMed ID: 3731919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of josamycin against aerobic gram-positive cocci and anaerobes.
    Westerman EL; Williams TW; Moreland N
    Antimicrob Agents Chemother; 1976 Jun; 9(6):988-93. PubMed ID: 7189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of midecamycin diacetate, a 16-membered macrolide, against Streptococcus pyogenes isolated in France, 1995-1999.
    Schlegel L; Merad B; Rostane H; Broc V; Bouvet A
    Clin Microbiol Infect; 2001 Jul; 7(7):362-6. PubMed ID: 11531981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibacterial activity of rokitamycin against fresh clinical isolates].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Suzuki K; Fukayama S; Ishihara R; Oda S
    Jpn J Antibiot; 1992 Dec; 45(12):1609-21. PubMed ID: 1289579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance of Mycoplasma pneumoniae to macrolide and analogous antibiotics.
    Suzaki K
    Sci Rep Res Inst Tohoku Univ Med; 1979 Dec; 26(3-4):71-91. PubMed ID: 121168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Susceptibility to macrolides against Mycoplasma pneumoniae isolated during 7 years].
    Arai S; Ohishi M; Shigematsu H
    Kansenshogaku Zasshi; 1994 Feb; 68(2):201-8. PubMed ID: 8151146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination.
    Neu HC; Chin NX; Gu JW
    J Antimicrob Chemother; 1992 Jul; 30 Suppl A():83-94. PubMed ID: 1328138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility of Ureaplasma urealyticum clinical isolates to new macrolides.
    Kanamoto Y; Miyake Y; Suginaka H; Usui T
    Chemotherapy; 1991; 37(4):256-9. PubMed ID: 1790724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rokitamycin and other macrolide antibiotics on Mycoplasma pneumoniae in L cells.
    Misu T; Arai S; Furukawa M; Yamamoto Y; Miyazaki T
    Antimicrob Agents Chemother; 1987 Nov; 31(11):1843-5. PubMed ID: 3124740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant increase in the prevalence of erythromycin-resistant, clindamycin- and miocamycin-susceptible (M phenotype) Streptococcus pyogenes in Spain.
    Alós JI; Aracil B; Oteo J; Gómez-Garcés JL;
    J Antimicrob Chemother; 2003 Feb; 51(2):333-7. PubMed ID: 12562699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.